INO 5150

Drug Profile

INO 5150

Alternative Names: INO-5150; Prostate cancer DNA vaccine - Inovio

Latest Information Update: 16 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Inovio Pharmaceuticals
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 06 Jun 2017 Adverse events data from a phase I trial in Prostate cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
  • 12 Jul 2016 Inovio Pharmaceuticals completes enrolment in its phase I trial for Prostate cancer in USA , (NCT02514213)
  • 27 Jul 2015 Phase-I clinical trials in Prostate cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top